Reagents and methods for smooth muscle therapies
AssigneeArizona Board of Regents
InventorsColleen Brophy, Alyssa Panitch, Padmini Komalavilas, Brandon Seal, Lokesh Joshi
Life of this patent
Estimating the term…
Abstract
The present invention provides novel polypeptides comprising heat shock protein 20 (HSP20)-derived polypeptides to treat or inhibit smooth muscle vasospasm, as well to treat and inhibit smooth muscle cell proliferation and migration.
Claims12
A method for inhibiting smooth muscle cell proliferation and/or migration, comprising contacting the smooth muscle cells with an amount effective to inhibit smooth muscle cell proliferation and/or migration of the following polypeptide:
- X2-SEQ ID NO:
- 300-X6
- X2 is absent or is a cell transduction domain;
- X6 is absent or is a cell transduction domain;
- and wherein at least one of X2 and
- X6 comprise a transduction domain;
- (SEQ ID NO:
- 300) is Trp Leu Arg Arg Ala Ser Ala Pro Leu Pro Gly Leu Lys;
- and
- the serine in SEQ ID NO:
- 300 is phosphorylated.
A method for inhibiting smooth muscle cell proliferation and/or migration, comprising contacting the smooth muscle cells with an amount effective to inhibit smooth muscle cell proliferation and/or migration of the following polypeptide:
- X2-SEQ ID NO:
- 300
- X2 is a cell transduction domain;
- (SEQ ID NO:
- 300) is Trp Leu Arg Arg Ala Ser Ala Pro Leu Pro Gly Leu Lys;
- and
- the serine in SEQ ID NO:
- 300 is phosphorylated.
A method for treating or inhibiting a disorder selected from the group consisting of intimal hyperplasia, stenosis, restenosis, and/or atherosclerosis, comprising contacting a subject in need thereof with an amount effective to treat or inhibit intimal hyperplasia, stenosis, restenosis, and/or atherosclerosis with the following polypeptide:
- X2-SEQ ID NO:
- 300-X6
- X2 is absent or is a cell transduction domain;
- X6 is absent or is a cell transduction domain;
- and wherein at least one of X2 and
- X6 comprise a transduction domain;
- (SEQ ID NO:
- 300) is Trp Leu Arg Arg Ala Ser Ala Pro Leu Pro Gly Leu Lys;
- and
- the serine in SEQ ID NO:
- 300 is phosphorylated.
A method for treating or inhibiting a disorder selected from the group consisting of intimal hyperplasia, stenosis, restenosis, and/or atherosclerosis, comprising contacting a subject in need thereof with an amount effective to treat or inhibit intimal hyperplasia, stenosis, restenosis, and/or atherosclerosis of the following polypeptide:
- X2-SEQ ID NO:
- 300
- X2 is a cell transduction domain;
- (SEQ ID NO:
- 300) is Trp Leu Arg Arg Ala Ser Ala Pro Leu Pro Gly Leu Lys;
- and
- the serine in SEQ ID NO:
- 300 is phosphorylated.
A method for treating or inhibiting smooth muscle spasm, comprising contacting a subject in need thereof with an amount effective to inhibit vasoconstriction of the following polypeptide:
- X2-SEQ ID NO:
- 300-X6
- X2 is absent or is a cell transduction domain;
- X6 is absent or is a cell transduction domain;
- and wherein at least one of X2 and
- X6 comprise a transduction domain;
- (SEQ ID NO:
- 300) is Trp Leu Arg Arg Ala Ser Ala Pro Leu Pro Gly Leu Lys;
- and
- the serine in SEQ ID NO:
- 300 is phosphorylated.
A method for treating or inhibiting smooth muscle spasm, comprising contacting a subject in need thereof with an amount effective to inhibit vasoconstriction of the following polypeptide
- X2-SEQ ID NO:
- 300
- X2 is a cell transduction domain;
- (SEQ ID NO:
- 300) is Trp Leu Arg Arg Ala Ser Ala Pro Leu Pro Gly Leu Lys;
- and
- the serine in SEQ ID NO:
- 300 is phosphorylated.
A method of reducing graft failure in a subject with a graft, comprising administering to the subject an effective amount of the following polypeptide
- X2-SEQ ID NO:
- 300-X6
- X2 is absent or is a cell transduction domain;
- X6 is absent or is a cell transduction domain;
- and wherein at least one of X2 and
- X6 comprise a transduction domain;
- (SEQ ID NO:
- 300) is Trp Leu Arg Arg Ala Ser Ala Pro Leu Pro Gly Leu Lys;
- and
- the serine in SEQ ID NO:
- 300 is phosphorylated.
A method of reducing graft failure in a subject with a graft, comprising administering to the subject an effective amount of the following polypeptide:
- X2-SEQ ID NO:
- 300
- X2 is a cell transduction domain;
- (SEQ ID NO:
- 300) is Trp Leu Arg Arg Ala Ser Ala Pro Leu Pro Gly Leu Lys;
- and
- the serine in SEQ ID NO:
- 300 is phosphorylated.
Dependencies are inferred from the claim text.